Literature DB >> 1350522

Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy.

L Fananapazir1, R O Cannon, D Tripodi, J A Panza.   

Abstract

BACKGROUND: Patients with obstructive hypertrophic cardiomyopathy (HCM) with symptoms refractory to drugs (beta-blockers or verapamil) are candidates for cardiac surgery (left ventricular septal myectomy or mitral valve replacement). The present study examines prospectively the ability of dual-chamber (DDD) pacing to improve symptoms and relieve left ventricular outflow obstruction in such patients. METHODS AND
RESULTS: Forty-four consecutive patients with obstructive HCM who had failed to benefit from pharmacotherapy underwent treadmill exercise tests, echocardiography, and cardiac catheterization before and 1.5-3 months after implantation of a DDD pacemaker. Symptoms (angina, dyspnea, palpitations, presyncope, and syncope), New York Heart Association functional class status (1.7 +/- 0.7 versus 3.4 +/- 0.5, p less than 0.00001), and exercise durations were improved at follow-up evaluation. This was associated with significant reduction in left ventricular outflow tract gradient (38 +/- 38 versus 87 +/- 43 mm Hg, p less than 0.0001) and significant increases in cardiac output and systemic arterial pressures. Notably, when pacing was discontinued and comparisons were made in sinus rhythm, treadmill exercise durations were greater and left ventricular outflow tract gradients were less at the follow-up evaluation compared with the baseline study.
CONCLUSIONS: DDD pacing is an effective alternative to surgery in most patients with obstructive HCM with drug-refractory symptoms. The beneficial effects of pacing continue to be evident when pacing is acutely discontinued.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350522     DOI: 10.1161/01.cir.85.6.2149

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

Review 1.  Emerging indications for permanent pacing.

Authors:  D L Wolbrette; G V Naccarelli
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

2.  Long-term results of apico-aortic valved conduit for severe idiopathic hypertrophic subaortic stenosis.

Authors:  A Renzulli; R Gregorio; M De Feo; G Ismeno; F E Covino; M Cotrufo
Journal:  Tex Heart Inst J       Date:  2000

3.  Unmasking the truth.

Authors:  D Cullington; S Esmail; S Hurren; J G F Cleland; A L Clark; M F Alamgir
Journal:  BMJ Case Rep       Date:  2011-01-12

Review 4.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

5.  Pacing for hypertrophic obstructive cardiomyopathy does it work?

Authors:  Q Zaidi; H Zaky; O Aljassim
Journal:  J Saudi Heart Assoc       Date:  2009-08-05

6.  Pacing for obstructive hypertrophic cardiomyopathy.

Authors:  L Kappenberger
Journal:  Br Heart J       Date:  1995-02

7.  Imaging asynchronous mechanical activation of the paced heart with tagged MRI.

Authors:  E R McVeigh; F W Prinzen; B T Wyman; J E Tsitlik; H R Halperin; W C Hunter
Journal:  Magn Reson Med       Date:  1998-04       Impact factor: 4.668

Review 8.  Potential mechanisms of improvement after various treatments for hypertrophic obstructive cardiomyopathy.

Authors:  R D Leachman
Journal:  Tex Heart Inst J       Date:  1995

9.  Reversible ischaemia in hypertrophic cardiomyopathy.

Authors:  H Thomson; W Fong; W Stafford; M Frenneaux
Journal:  Br Heart J       Date:  1995-09

10.  DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience.

Authors:  A K Slade; N Sadoul; L Shapiro; L Chojnowska; J P Simon; R C Saumarez; B Dodinot; A J Camm; W J McKenna; E Aliot
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.